TC Biopharm (Holdings) Plc (TCBP)
NASDAQ: TCBP · Real-Time Price · USD
0.630
+0.035 (5.83%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform.

Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.

The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

TC Biopharm (Holdings) Plc
TC Biopharm (Holdings) logo
Country United Kingdom
Founded 2013
IPO Date Feb 11, 2022
Industry Biotechnology
Sector Healthcare
Employees 41
CEO Bryan Kobel

Contact Details

Address:
Maxim 1, 2 Parklands Way
Motherwell, ML1 4WR
United Kingdom
Phone 44 14 1433 7557
Website tcbiopharm.com

Stock Details

Ticker Symbol TCBP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency GBP
IPO Price $4.25
CIK Code 0001872812
CUSIP Number 87807D103
ISIN Number US87807D4007
SIC Code 2836

Key Executives

Name Position
Bryan Leland Kobel Chief Executive Officer and Director
Martin Edward Thorp Chief Financial Officer and Director
Christopher Camarra Executive Vice President of Communications
Dr. Lauren Bor Ph.D. Head of Commercial Development Division

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 11, 2024 6-K Report of foreign issuer
Aug 30, 2024 6-K Report of foreign issuer
Aug 29, 2024 424B4 Prospectus
Aug 28, 2024 EFFECT Notice of Effectiveness
Aug 28, 2024 F-1MEF Filing
Aug 23, 2024 F-1/A [Amend] Registration statement for certain foreign private issuers
Aug 23, 2024 6-K Report of foreign issuer
Aug 22, 2024 UPLOAD Filing
Aug 16, 2024 F-1 Registration statement for certain foreign private issuers